Alpha Tau to Participate at Jefferies Global Healthcare Conference in London

Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), an Israeli oncology therapeutics company, is set to participate in the Jefferies Global Healthcare Conference in London on November 18-19, 2025. The company's Chief Financial Officer, Raphi Levy, will be available for one-on-one investor meetings during the event, providing an opportunity for stakeholders to engage directly with company leadership. Interested parties are encouraged to coordinate with their Jefferies representative to schedule a meeting.

Founded in 2016, Alpha Tau is at the forefront of developing innovative treatments for cancer, specifically focusing on its proprietary therapy, Alpha DaRT® (Diffusing Alpha-emitters Radiation Therapy). This cutting-edge technology was originally devised by notable academics Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University, demonstrating robust scientific roots and potential.

Alpha DaRT® employs a unique method of delivering alpha-radiation directly to solid tumors through the use of radium-224 impregnated sources. As the radium decays, it emits high-energy alpha particles that target the tumor while minimizing damage to surrounding healthy tissues. This localized treatment approach aims to significantly enhance tumor destruction while reducing side effects, offering a promising alternative to conventional therapies.

The upcoming Jefferies Global Healthcare Conference represents a critical platform for Alpha Tau to showcase its innovative treatment pipeline and engage with the investment community. With the growing demand for effective cancer therapies, Alpha Tau's participation could provide valuable insights into its future strategies and clinical developments. Investors and analysts keen on learning more about Alpha Tau's trajectory in the therapeutic oncology space will find this event a prime opportunity for engagement. For further inquiries, Alpha Tau’s investor relations team can be reached at IR@alphatau.com.

Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW) is making waves in the oncology space with its pioneering alpha-radiation therapy, Alpha DaRT. As the company prepares for the Jefferies Global Healthcare Conference in London on November 18-19, 2025, investors should pay close attention to this engagement, particularly the opportunity for one-on-one meetings with CFO Raphi Levy.

Alpha Tau’s approach to treating solid tumors through innovative intratumoral delivery of radium-224 positions it at the forefront of cancer therapeutics. This mechanism’s potential for highly localized treatment means it could disrupt traditional oncology methods, offering a specialized alternative that aims to minimize damage to surrounding healthy tissues. With ongoing research and early clinical results potentially favorable, investor sentiment can be influenced by the insights shared during the conference.

For investors, Alpha Tau presents an intriguing opportunity, especially as oncology continues to be a major focus area for healthcare investment. A successful presentation at Jefferies could not only increase visibility and investor interest but also provide vital news updates on clinical trials and regulatory progress. Pay attention to the market reactions post-conference, as well as any strategic partnerships or funding announcements that may arise from discussions at this event, which are crucial for Alpha Tau’s growth roadmap.

In summary, attending the Jefferies Global Healthcare Conference positions Alpha Tau as a key player in the oncology sector. Investors should look for actionable insights and developments from this event that can propel the company's shares higher. It's advisable to monitor the sentiment and market activity leading up to and following the conference to gauge Alpha Tau's trajectory in the competitive landscape of cancer treatment solutions.